Ashish K Rehni1,2, Vibha Shukla1,2, Hever Navarro Quero3, Carlos Bidot3, Conner R Haase1,2, Ensign Anise A Crane1,2, Shivam G Patel1,2, Sebastian Koch1, Yeon S Ahn3, Wenche Jy3, Kunjan R Dave1,2,4. 1. 1 Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, University of Miami Miller School of Medicine, Miami, FL, USA. 2. 2 Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA. 3. 3 Wallace H Coulter Platelet Laboratory, Division of Hematology and Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. 4. 4 Neuroscience Program, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract
BACKGROUND: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. METHODS AND RESULTS: RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. CONCLUSIONS: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.
BACKGROUND: Uncontrollable bleeding is a major cause of mortality and morbidity worldwide. Effective hemostatic agents are urgently needed. Red cell microparticles (RMPs) are a highly promising hemostatic agent. This study evaluated the safety profile of RMPs preliminary to clinical trial. METHODS AND RESULTS:RMPs were prepared from type O+ human red blood cell by high-pressure extrusion. Male rats were treated with RMPs either a 1 × bolus, or 4 × or 20 × administered over 60 minutes. The vehicle-treated group was used as a control. Effects on physiological parameters were evaluated; namely, blood pressure, body and head temperature, hematocrit, and blood gases. We did not observe any adverse effects of RMPs on these physiological parameters. In addition, brain, heart, and lungs of rats treated with 4 × dose (bolus followed by infusion over 60 minutes) or vehicle were examined histologically for signs of thrombosis or other indications of toxicity. No thrombosis or indications of toxicity in brain, heart, or lungs were observed. Studies revealed that RMPs were distributed mainly in liver, spleen, and lymph nodes, and were potentially excreted through the kidneys. CONCLUSIONS: Our study indicates that RMP administration appears not to have any negative impact on the parameters studied and did not produce thrombosis in heart, brain, and lungs. However, more detailed long-term studies confirming the safety of RMP as a hemostatic agent are warranted.
Authors: Sonia Martinez-Caballero; Pablo M V Peixoto; Kathleen W Kinnally; María Luisa Campo Journal: Anal Biochem Date: 2007-01-22 Impact factor: 3.365
Authors: Sara Orsini; Patrizia Noris; Loredana Bury; Paula G Heller; Cristina Santoro; Rezan A Kadir; Nora C Butta; Emanuela Falcinelli; Ana Rosa Cid; Fabrizio Fabris; Marc Fouassier; Koji Miyazaki; Maria Luisa Lozano; Pamela Zúñiga; Claire Flaujac; Gian Marco Podda; Nuria Bermejo; Remi Favier; Yvonne Henskens; Emmanuel De Maistre; Erica De Candia; Andrew D Mumford; Gul Nihal Ozdemir; Ibrahim Eker; Paquita Nurden; Sophie Bayart; Michele P Lambert; James Bussel; Barbara Zieger; Alberto Tosetto; Federica Melazzini; Ana C Glembotsky; Alessandro Pecci; Marco Cattaneo; Nicole Schlegel; Paolo Gresele Journal: Haematologica Date: 2017-04-06 Impact factor: 9.941
Authors: Wenche Jy; Ashish K Rehni; Carlos Bidot; Hever Navarro-Quero; Conner R Haase; Sebastian Koch; Yeon S Ahn; Kunjan R Dave Journal: Front Pharmacol Date: 2018-06-11 Impact factor: 5.810
Authors: Laily D Zubairova; Roza M Nabiullina; Chandrasekaran Nagaswami; Yuriy F Zuev; Ilshat G Mustafin; Rustem I Litvinov; John W Weisel Journal: Sci Rep Date: 2015-12-04 Impact factor: 4.379
Authors: Johannes Boltze; Jaroslaw A Aronowski; Jerome Badaut; Marion S Buckwalter; Mateo Caleo; Michael Chopp; Kunjan R Dave; Nadine Didwischus; Rick M Dijkhuizen; Thorsten R Doeppner; Jens P Dreier; Karim Fouad; Mathias Gelderblom; Karen Gertz; Dominika Golubczyk; Barbara A Gregson; Edith Hamel; Daniel F Hanley; Wolfgang Härtig; Friedhelm C Hummel; Maulana Ikhsan; Miroslaw Janowski; Jukka Jolkkonen; Saravanan S Karuppagounder; Richard F Keep; Inga K Koerte; Zaal Kokaia; Peiying Li; Fudong Liu; Ignacio Lizasoain; Peter Ludewig; Gerlinde A S Metz; Axel Montagne; Andre Obenaus; Alex Palumbo; Monica Pearl; Miguel Perez-Pinzon; Anna M Planas; Nikolaus Plesnila; Ami P Raval; Maria A Rueger; Lauren H Sansing; Farida Sohrabji; Charlotte J Stagg; R Anne Stetler; Ann M Stowe; Dandan Sun; Akihiko Taguchi; Mickael Tanter; Sabine U Vay; Raghu Vemuganti; Denis Vivien; Piotr Walczak; Jian Wang; Ye Xiong; Marietta Zille Journal: Front Aging Neurosci Date: 2021-01-28 Impact factor: 5.750